# Peter Bartenstein

Source: https://onco.cc/people/peter-bartenstein/  
OnCo record `peter-bartenstein` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Peter Bartenstein is a nuclear medicine head whose department is a leading European PSMA theranostics centre.

## Summary

Peter Bartenstein is Director of the Department of Nuclear Medicine at LMU Klinikum München. His specialisms are nuclear medicine, PSMA theranostics and neuro-imaging. His department is a leading European centre for PSMA PET and lutetium-177 PSMA radioligand therapy, and it co-developed 177Lu-PSMA-I&T. His papers include a dosimetry study of 177Lu-DKFZ-PSMA-617 as a new radiopharmaceutical for metastatic prostate cancer, the first clinical results of 18F-SiFAlin-TATE PET for imaging neuroendocrine tumours, and a European Urology study showing that 68Ga-PSMA PET/CT accurately stages lymph node regions before dissection in prostate cancer. His publications are listed on PubMed.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Director, Department of Nuclear Medicine, LMU Munich
- Specialisms: Nuclear medicine; PSMA theranostics; Neuro-imaging

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Bartenstein%20P%5BAuthor%5D%20PSMA

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- technologies: [PSMA PET](https://onco.cc/technologies/psma-pet/), [Radioligand therapy (beta emitters)](https://onco.cc/technologies/radioligand-therapy/)
- targets: [PSMA](https://onco.cc/targets/psma/)
- drugs: [177Lu-PSMA-I&T](https://onco.cc/drugs/lu177-psma-it/)
- institutions: [LMU Klinikum München](https://onco.cc/institutions/lmu-munich/)

---
JSON: https://onco.cc/api/v1/entities/peter-bartenstein.json